Sino Medical Sciences Technology In (688108) - Total Liabilities
Based on the latest financial reports, Sino Medical Sciences Technology In (688108) has total liabilities worth CN¥407.00 Million CNY (≈ $59.56 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Sino Medical Sciences Technology In to assess how effectively this company generates cash.
Sino Medical Sciences Technology In - Total Liabilities Trend (2016–2024)
This chart illustrates how Sino Medical Sciences Technology In's total liabilities have evolved over time, based on quarterly financial data. Check 688108 financial resilience to evaluate the company's liquid asset resilience ratio.
Sino Medical Sciences Technology In Competitors by Total Liabilities
The table below lists competitors of Sino Medical Sciences Technology In ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Taiwan FamilyMart Co Ltd
TWO:5903
|
Taiwan | NT$70.88 Billion |
|
Shandong Intco Recycling Resources Co Ltd
SHG:688087
|
China | CN¥4.30 Billion |
|
Hangzhou Zhongtai Cryogenic Technology Corp
SHE:300435
|
China | CN¥1.24 Billion |
|
Jinan Acetate Chemical Co Ltd
TW:4763
|
Taiwan | NT$1.77 Billion |
|
361 Degrees International Limited
F:36L
|
Germany | €3.61 Billion |
|
PDF Solutions Inc
NASDAQ:PDFS
|
USA | $147.68 Million |
|
Whirlpool of India Limited
NSE:WHIRLPOOL
|
India | Rs23.97 Billion |
|
SRG Global Ltd
AU:SRG
|
Australia | AU$591.77 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Sino Medical Sciences Technology In's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688108 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sino Medical Sciences Technology In's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sino Medical Sciences Technology In (2016–2024)
The table below shows the annual total liabilities of Sino Medical Sciences Technology In from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥402.22 Million ≈ $58.86 Million |
+24.08% |
| 2023-12-31 | CN¥324.17 Million ≈ $47.44 Million |
+79.96% |
| 2022-12-31 | CN¥180.13 Million ≈ $26.36 Million |
+14.06% |
| 2021-12-31 | CN¥157.92 Million ≈ $23.11 Million |
+13.10% |
| 2020-12-31 | CN¥139.63 Million ≈ $20.43 Million |
+30.36% |
| 2019-12-31 | CN¥107.11 Million ≈ $15.67 Million |
+2.18% |
| 2018-12-31 | CN¥104.83 Million ≈ $15.34 Million |
+1.16% |
| 2017-12-31 | CN¥103.62 Million ≈ $15.16 Million |
+32.74% |
| 2016-12-31 | CN¥78.06 Million ≈ $11.42 Million |
-- |
About Sino Medical Sciences Technology In
Sino Medical Sciences Technology Inc., a medical device company, engages in the research, development, production, and distribution of interventional medical devices in China. Its products include coronary drug stents, coronary balloons, intracranial rapid exchange balloons, and intracranial drug-eluting stents. The company was founded in 2007 and is headquartered in Tianjin, China.